Nov 11 (Reuters) - European Medicines Agency (EMA):
* EMA: EMA PUBLISHED NEW SAFETY UPDATES FOR COMIRNATY, COVID-19 VACCINE JANSSEN, SPIKEVAX AND VAXZEVRIA: 11/11/2021
* EMA - THERE IS CURRENTLY INSUFFICIENT EVIDENCE OF A POSSIBLE LINK BETWEEN COMIRNATY AND VERY RARE CASES OF MULTISYSTEM INFLAMMATORY SYNDROME (MIS)
* EMA ON COMIRNATY - FURTHER ASSESSMENT OF MYOCARDITIS AND PERICARDITIS IS ONGOING
* EMA: THERE IS CURRENTLY INSUFFICIENT EVIDENCE OF A POSSIBLE LINK BETWEEN SPIKEVAX AND VERY RARE CASES OF MULTISYSTEM INFLAMMATORY SYNDROME
* EMA SAYS CVST WILL BE ADDED TO THE PRODUCT INFORMATION AS A SIDE EFFECT OF ASTRAZENECA COVID-19 VACCINE VAXZEVRIA.
* EMA: PRAC HAS STARTED A REVIEW OF A SAFETY SIGNAL TO ASSESS REPORTS OF CAPILLARY LEAK SYNDROME IN PEOPLE WHO WERE VACCINATED WITH SPIKEVAX
* EMA SAYS CVST WITHOUT THROMBOCYTOPENIA HAS BEEN OBSERVED VERY RARELY FOLLOWING VACCINATION WITH ASTRAZENECA COVID-19 VACCINE VAXZEVRIA
* EMA: AT THIS STAGE, IT IS NOT YET CLEAR WHETHER THERE IS CAUSAL ASSOCIATION BETWEEN SPIKEVAX VACCINATION AND REPORTS OF CAPILLARY LEAK SYNDROME
* EMA - PRAC HAS ASKED COMPANY THAT MARKETS COMIRNATY TO PERFORM IN-DEPTH REVIEW OF ALL PUBLISHED DATA ON ASSOCIATION OF MYOCARDITIS, PERICARDITIS WITH VACCINE
* EMA: THERE IS CURRENTLY INSUFFICIENT EVIDENCE OF POSSIBLE LINK BETWEEN COVID-19 VACCINE JANSSEN AND EITHER MIS OR MENSTRUAL DISORDERS Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.